A Network Pharmacological Approach to Investigate the Mechanism of Action of Active Ingredients of Epimedi Herba and Their Potential Targets in Treatment of Alzheimer’s Disease

Yajuan Li
Qin Yang
Yang Yu

Department of Histology and Embryology, School of Basic Medical Sciences, Southwest Medical University, Luzhou, Sichuan, P.R. China

Background: *Epimedi Herba* is a traditional Chinese herbal medicine used to treat central nervous system diseases such as Alzheimer’s disease in China. However, the pharmacological mechanism is unclear. To investigate the mechanisms of *Epimedi Herba* in the treatment of Alzheimer’s disease, we assessed effective compounds, corresponding targets, and related pathways of *Epimedi Herba* in the treatment of Alzheimer’s disease based on network pharmacology.

Material/Methods: The active components and targets of *Epimedi Herba* were obtained through the TCMSP database and the DrugBank database. The DisGeNET database and GeneCards database were used to search for Alzheimer’s disease targets. The common targets of components and disease were obtained by Wayne diagram. Gene ontology (GO) analysis and enrichment analysis of the Kyoto Encyclopedia of Genes and Genomes (KEGG) were performed using the DAVID database. The component-target-pathway interaction network model was constructed using Cytoscape software. Auto Duck Vina software was used for molecular docking to analyze the affinity of the key ingredients and the main targets.

Results: We screened 17 active ingredients and 27 key targets of *Epimedi Herba* in the treatment of Alzheimer’s disease, which were related to the HIF-1 signaling pathway, TNF signaling pathway, PI3K-Akt signaling pathway, NF-kB signaling pathway, VEGF signaling pathway, and sphingolipid signaling pathway.

Conclusions: Based on network pharmacology, the multi-component, multi-target, and multi-pathway characteristics of *Epimedi Herba* in the treatment of Alzheimer’s disease were explored. Our results provide new ideas for future pharmacological and experimental research on *Epimedi Herba* in the treatment of Alzheimer’s disease.

MeSH Keywords: Alzheimer Disease • Medicine, Chinese Traditional • Pharmacologic Actions

Full-text PDF: https://www.medscimonit.com/abstract/index/idArt/926295
Background

*Epimedii Herba* is a traditional Chinese herbal medicine derived from the genus *Epimedium* of the Berberidaceae family, and its main chemical component is flavonoids [1]. It has been reported in the literature that it has a wide range of activities, such as improving cerebral blood flow to treat central nervous system diseases, promoting blood circulation, reducing depression symptoms, improving memory ability, and preventing brain damage caused by inflammation of nerve cells. It has important clinical medicinal value [2–4].

Alzheimer’s disease (AD) is a degenerative disease of the nervous system. Because progressive cognitive function declines and cognitive behavior changes often occur in clinical development [5], it imposes a huge burden on the family and society [6]. The cause of the disease is still unclear [7]. Age is the biggest risk factor for AD, and the likelihood of suffering from Alzheimer’s disease increases with age [6]. The main pathological feature is the aggregation of β-amyloid protein (Aβ) and amyloid plaques of tau protein [5]. Traditional Chinese medicine often describes its symptoms as “dementia” and “forgetfulness” [8]. In the theory of traditional Chinese medicine, the elderly often have physiological characteristics of kidney and spleen insufficiency, which are the pathological basis of AD [9,10]. The book “Shen Nong Bencao Jing” emphasizes that brain-nourishing medicine is mainly based on kidney-nourishing Chinese medicine [11]. Therefore, tonifying the kidneys and strengthening the spleen are common methods of traditional Chinese medicine used to treat AD. *Epimedii Herba* is classified as a kidney tonic in China. It is the most well-known plant with aphrodisiac effects used in Asian countries [12]. It is used to nourish the kidney and improve AD. *Epimedii Herba* can improve AD and has antidepressant and neuroprotective effects [13]. *Epimedii Herba* thus plays an important role in the treatment of Alzheimer’s disease.

Network pharmacology is the integration of various informatics approaches, including bioinformatics, systems biology, and pharmacology. It can analyze the interaction from multiple perspectives of drug-component-target-disease. Network pharmacology can explore the mechanism of action of drugs on diseases systemically and holistically, which is consistent with the holistic and systematic approach of traditional Chinese medicine to disease treatment [14]. To explore the beneficial effect of *Epimedii Herba* on Alzheimer’s disease, the present study used a network pharmacology approach to comprehensively study the active ingredients of *Epimedii Herba* and the potential mechanism of action in treatment of Alzheimer’s disease. To provide a theoretical basis for the clinical application of *Epimedii Herba* in the treatment of Alzheimer’s disease, we further explored the synergistic relationship between the components, targets, and pathways of *Epimedii Herba*.

Material and Methods

Component collection and screening of *Epimedii Herba*

In the traditional Chinese medicine system pharmacology database and analysis platform TCMSP (http://tcmspew.com/), we used “Epimedi Herba” as a keyword to search for chemical components. According to ADME (absorption, distribution, metabolism, and excretion) related to chemical properties, the oral route is the most important and convenient way to transport drugs through the systemic circulation, and oral bioavailability (OB) is usually used to objectively evaluate whether a drug molecule has good absorbability [15]. Drug-likeness (DL) is a qualitative concept used in drug design [16]. According to the drug screening standard recommended by TCMSP [17], the active ingredient of *Epimedii Herba* was obtained by using the drug screening standard 20 with OB ≥30% and DL ≥0.18 [18] (Table 1).

Collection of targets related to active ingredients

The TCMSP database was used to find corresponding relevant targets of the active ingredients of *Epimedii Herba*. Then, targets were selected from DrugBank (https://www.drugbank.ca/) [19]. Through the UniProt database (https://www.uniprot.org/) [20], we collected the gene names of the corresponding species.

Collection of AD-related disease targets

The target genes related to AD were collected from 2 databases: the DisGeNET database (http://www.disenet.org/) [21] and the GeneCards database (https://www.genecards.org/) [22]. We used “Alzheimer’s disease” as a search term and set the species as Homo sapiens. We screened for disease targets based on the score size and deleted the repeated options in the search results to obtain the final AD target genes.

Network model construction

Network analysis provides a scientific explanation of the complex relationships among traditional Chinese medicines, compounds, genes, and diseases. In the present study, network construction was carried out using Cytoscape 3.7.2 software [23] with the following 3 approaches:

1) For the chemical components of *Epimedii Herba* and its related target genes, the active components and corresponding targets of *Epimedii Herba* were summarized and then introduced into the Cytoscape 3.7.2 software to construct the network.

2) For the common targets of *Epimedii Herba* component targets and AD-related targets, to analyze the interaction between the *Epimedii Herba*-related targets and the disease-related targets, we inputted the drug component targets and...
Table 1. Potential active components of *Epimedii Herba*.

| Molecule Name                                      | OB (%) | DL  |
|----------------------------------------------------|--------|-----|
| MOL000622 Magnograndiolide                         | 63.71  | 0.19|
| MOL004367 Olivil                                    | 62.23  | 0.41|
| MOL004388 6-hydroxy-11,12-dimethoxy-2,2-dimethyl-1,8-dioxo-2,3,4,8-tetrahydro-1H-isochromeno[3,4-h]isoquinolin-2-ium | 60.64  | 0.66|
| MOL004382  Yinyanghuo A                             | 56.96  | 0.77|
| MOL004396 1,2-bis(4-hydroxy-3-methoxyphenyl)propan-1,3-diol | 52.31  | 0.22|
| MOL004386 Yinyanghuo E                             | 51.63  | 0.55|
| MOL004391 8-(3-methylbut-2-enyl)-2-phenyl-chromone | 48.54  | 0.25|
| MOL000098 Quercetin                                 | 46.43  | 0.28|
| MOL004384 Yinyanghuo C                             | 45.67  | 0.5 |
| MOL004373 Anhydroicaritin                           | 45.41  | 0.44|
| MOL01645 Linoleyl acetate                          | 42.1   | 0.2 |
| MOL00422 Kaempferol                                 | 41.88  | 0.24|
| MOL004394 Anhydroicaritin-3-O-alpha-L-rhamnoside   | 41.58  | 0.61|
| MOL004425 Icarin                                    | 41.58  | 0.61|
| MOL004380 C-Homoerythrinan, 1,6-didehydro-3,15,16-trimethoxy-,(3-beta) | 39.14  | 0.49|
| MOL003542 8-isopentenyl-kaempferol                  | 38.04  | 0.39|
| MOL001510 24-epicampesterol                         | 37.58  | 0.71|
| MOL000359 Sitosterol                                | 36.91  | 0.75|
| MOL001771 Poriferast-5-en-3beta-ol                  | 36.91  | 0.75|
| MOL000006 Luteolin                                  | 36.16  | 0.25|
| MOL003044 Chryseriol                                | 35.85  | 0.27|
| MOL001792 DFV                                       | 32.76  | 0.18|
| MOL004427 Icariside A7                              | 31.91  | 0.86|

3) For the active components of *Epimedii Herba* AD-related genes and pathways, the pathway enrichment of the common target proteins was carried out using the KEGG database to obtain the relevant signal pathways. The effective components, target proteins, and pathway information of *Epimedii Herba* were imported into Cytoscape 3.7.2 to construct the “component-target-pathway” network model.

**Enrichment analysis**

Go enrichment analysis and KEGG path enrichment analysis of key target genes were carried out through the DAVID online database [https://david.ncifcrf.gov/][25]. Then, we used OmicShare’s online data analysis platform tool (http://www.omicshare.com/tools) to draw a bubble chart.
We performed molecular docking of key components of *Epimedii Herba* in the network model with the targets and then obtained the protein crystal complexes of the main targets in the PDB database [26]. PyMOL software separated the original ligand from the target protein and removed the water molecule, phosphate, and other inactive related ligands of the target protein [27]. We imported the 2D structure of key small molecule compounds into ChemBio3D software and exported the format of mol2 to save its 3D structure (ChemBioOffice 2014). In Auto Dock vina software, we imported the 3D structures of small molecules and target proteins and exported the format of pdbqt. Then, we docked the molecules between target proteins to observe their affinity. Auto Dock vina is free software. Compared with the earlier product, Auto Dock, it has higher precision and faster calculation speed, and it can improve the speed and accuracy of docking [28].

**Results**

**Screening of active ingredients of Epimedium**

TCMSP, a database of systems pharmacology for drug discovery from herbal medicines, includes 499 Chinese herbal medicines...
and 29384 ingredients, and provides drug targets and diseases of each active compound, with unique ability to identify drug target networks and drug disease networks [19]. Searching for the chemical compositions of *Epimedii Herba* from the TCMSP database, we obtained 130 chemical ingredients. The screening conditions OB ³ 30%, DL ³ 0.18 were set and 23 active ingredients of *Epimedii Herba* were finally collected (Table 1).

**Collection and screening of target information**

Target proteins corresponding to 23 active components of *Epimedii Herba* were collected from the TCMSP database. We selected them from DrugBank and obtained 129 target proteins. The corresponding gene names were transformed through the UniProt database and the results were imported into Cytoscape 3.7.2 software to construct an active ingredient-target network of *Epimedii Herba* (Figure 1). In Figure 1, there are 153 nodes and 381 edges. The active ingredients of *Epimedii Herba* in the inner circle are represented by yellow arrow nodes and the gene targets in the outer circle are represented by green circular nodes. Compounds with larger degree values including: MOL000098 (quercetin) degree value=74, MOL000422 (kaempferol) degree value=42, MOL004380 (C-Homoerythrinan, 1,6-didehydro-3,15,16-trimethoxy-, (3.beta.)) degree value=37, MOL004373 (Anhydroicaritin) degree value=35, MOL004391 (8-(3-methylbut-2-enyl)-2-phenyl-chromone) degree value=30, MOL000006 (luteolin) degree value=29, MOL003044 (Chryseriol)

**Figure 2.** Common Gene Targets of *Epimedii Herba* and AD.

**Figure 3.** Analysis of key target genes of *Epimedii Herba* against AD. (A) PPI network diagram of Key Targets. (B) Interaction network of targets for *Epimedii Herba* against AD. (C) Distribution of degree. (D) Betweenness centrality. The size and color of the nodes are proportional to degree centrality by topology analysis.
degree value=17, may be the main material basis of Epimedi Herba in the treatment of AD.

GeneCards is a comprehensive, authoritative compendium of annotative information on human genes, and DisGeNET is one of the largest available collections of genes and variants involved in human diseases. They can provide a variety of information such as genes and the relationship between genes and diseases. The GeneCards database was searched for genes related to Alzheimer's disease, and a total of 81 targets with scores $\geq 50$ were screened. We retrieved 122 targets from the DisGeNET database and 167 disease targets were obtained after deleting the duplicate targets. A total of 129 drug targets were retrieved from the TCMSP database. We took the intersection of drug targets and disease targets. Then, we drew a Venn diagram to obtain 27 key target genes for Epimedi Herba in the treatment of Alzheimer’s disease (Figure 2). The 27 targets were imported into the STRING 11.0 database to analyze protein-protein interactions (PPI) (Figure 3A). After that, the PPI results were exported as simple tabular text output (.tsv), and the TSV file was imported into Cytoscape (version 3.7.2) to draw the network diagram of target interaction. The size and color of the nodes are proportional to the degree. The larger the node and the darker the color, the more critical it is in the network. The results are shown in Figure 3B–3D. The average degree value of the PPI network is 6.30 and the average medium is 0.05. There are 5 targets whose degree value and medium were greater than the average. They are: APP (amyloid precursor protein, degree value=11; medium=0.4036), IL6 (interleukin 6, degree value=16; medium=0.181), VEGFA (vascular endothelial growth factor, degree value=12; medium=0.135), MAPK1 (mitogen-activated protein kinase 1, degree value=12;
medium=0.101), and TNF (tumor necrosis factor, degree value=12; medium=0.06).

**Enrichment analysis of biological functions and pathways**

To further explore the mechanism of *Epimedii Herba* on Alzheimer’s disease, the 27 targets were imported into the DAVID database. The goals were: HMOX1 NOS2 TNF INSR SLC6A4 DRD2 MPO MAOB MAPK1 F2 PTGS2 IL1B SOD1 ESR1 PON1 PTGS1 BCL2 CTSD TF VEGFA PPARG GSK3B CCL2 NOS3 IL6 APP SLC6A3. Official gene symbols were selected in the Select identifier, gene List was selected in the List type item, homo sapiens was selected in the background, and the threshold value P<0.05 was

![Figure 5. KEGG pathway enrichment of *Epimedii Herba* against AD. Top 20 pathways enriched based on target genes (the abscissa is the rich factor, the ordinate is pathway name, the size of the dot indicates the number of target genes, and the color represents the P-value).](image-url)
set. GO enrichment (Figure 4) and biological pathway analysis of KEGG (Figure 5) were carried out on the targets of Epimedii Herba in the treatment of AD. Figure 4 shows that in the molecular function of GO enrichment analysis, Epimedii Herba has a greater influence on protein homodimerization activity, heme binding, identical protein binding, peroxidase activity, and cytokine activity. In the cellular components, Epimedii Herba has effects on extracellular space, caveola, axon, and lysosome. In the biological processes, Epimedii Herba has a great impact on drug response, positive regulation of peptidyl-serine phosphorylation, regulation of blood pressure, response to hypoxia and toxic substance, and LPS-mediated signaling pathways. Figure 5 shows that the top 20 pathways involved in the treatment of Alzheimer's disease by Epimedii Herba are HIF-1 signaling pathway, TNF signaling pathway, PI3K-Akt signaling pathway, VEGF signaling pathway, and sphingolipid signaling pathway. Specific parameters are shown in Table 2. The HIF-1 signaling pathway with the lowest FDR value and the lowest P-value was taken as an example to study the enrichment of the anti-AD targets of Epimedii Herba. The results are shown in Figure 6.

### Component-target-pathway network model of Epimedii Herba

We used 27 target genes and their corresponding effective components and signaling pathways of Epimedii Herba to construct the “component-target-pathway” network model of Epimedii Herba (Figure 7). In Figure 7, there are a total of 59 nodes and 165 edges. Yellow, blue, and green represent the active components, targets, and regulatory pathways, respectively, of Epimedii Herba. Edges represent the interaction between these 3. The size of the node is proportional to the degree. The larger the node, the greater the effect in Alzheimer’s disease. The results

| Term                              | Count | Percentage (%) | P value  | Genes                                                                 |
|-----------------------------------|-------|----------------|----------|----------------------------------------------------------------------|
| HIF-1 signaling pathway           | 9     | 33.33          | 10^-4    | MAPK1, TF, IL6, HMOX1, BCL2, VEGFA, NOS3, NOS2, INSr                  |
| TNF signaling pathway             | 6     | 22.22          | 3.44x10^-5 | MAPK1, IL6, TNF, CCL2, PTGS2, IL1B                                    |
| Serotonergic synapse              | 6     | 22.22          | 4.11x10^-5 | MAPK1, APP, PTGS2, SLC6A4, PTGS1, MAOB                               |
| NOD-like receptor signaling pathway| 5     | 18.52          | 4.39x10^-5 | MAPK1, IL6, CCL2, IL1B                                               |
| Prion diseases                    | 4     | 14.81          | 2.36x10^-4 | MAPK1, IL6, IL1B, SOD1                                                |
| Rheumatoid arthritis              | 5     | 18.52          | 2.58x10^-4 | IL6, TNF, CCL2, VEGFA, IL1B                                           |
| Influenza A                       | 6     | 22.22          | 3.44x10^-4 | MAPK1, IL6, TNF, CCL2, GSK3B, IL1B                                   |
| Pathways in cancer                | 8     | 29.63          | 3.69x10^-4 | MAPK1, IL6, GSK3B, BCL2, VEGFA, NOS3, INSr                           |
| Insulin resistance                | 5     | 18.52          | 5.64x10^-4 | IL6, TNF, GSK3B, NOS3, INSr                                          |
| Malaria                           | 4     | 14.81          | 6.99x10^-4 | MAPK1, IL6, CCL2, IL1B                                               |
| Sphingolipid signaling pathway    | 5     | 18.52          | 8.39x10^-4 | MAPK1, TNF, BCL2, CTD, NOS3                                           |
| PI3K-Akt signaling pathway        | 7     | 25.93          | 1.2x10^-3 | MAPK1, IL6, GSK3B, BCL2, VEGFA, NOS3, INSr                           |
| VEGF signaling pathway            | 4     | 14.81          | 1.33x10^-3 | MAPK1, PTGS2, VEGFA, NOS3                                             |
| Non-alcoholic fatty liver disease (NAFLD) | 5     | 18.52          | 1.97x10^-3 | IL6, TNF, GSK3B, IL1B, INSr                                          |
| Alzheimer’s disease               | 5     | 18.52          | 2.91x10^-3 | MAPK1, APP, TNF, GSK3B, IL1B                                         |
| Salmonella infection              | 4     | 14.81          | 3.22x10^-3 | MAPK1, IL6, IL1B, NOS2                                               |
| NF-kappa B signaling pathway      | 4     | 14.81          | 3.68x10^-3 | TNF, PTGS2, BCL2, IL1B                                               |
| Graft-versus-host disease         | 3     | 11.11          | 6.25x10^-3 | IL6, TNF, IL1B                                                       |
| Toll-like receptor signaling pathway | 4   | 14.81         | 6.39x10^-3 | MAPK1, IL6, TNF, IL1B                                               |
| Amoebiasis                        | 4     | 14.81          | 6.39x10^-3 | IL6, TNF, IL1B, NOS2                                                |

*Table 2. KEGG signal pathway information.*
showed that prostaglandin-peroxide synthase 2 (PTGS2), mitogen-activated protein kinase 1 (MAPK1), prostaglandin-peroxide synthase 1 (PTGS1), tumor necrosis factor (TNF), estrogen receptor Body alpha (ESR1), and interleukin 6 (IL-6) are key nodes in the network, indicating that they are likely to be the core targets of *Epimedii Herba* treatment for Alzheimer’s disease. The “component-target-pathway” network shows that multiple components, multiple targets, and multiple pathways of Epimedium cooperate with each other in Alzheimer’s disease.

**Docking of key molecules with the major target proteins**

Quercetin with the largest degree of compound value was docked with the key target proteins prostaglandin-peroxide synthase 2 (PTGS2) in the network and the binding energy was -9.6 kcal/mol. Quercetin was docked with mitogen-activated protein kinase 1 (MAPK1) and the binding energy was –8 kcal/mol. The docking model is shown in Figure 8A, 8B. The docking binding energy of luteolin and tumor necrosis factor

**Figure 6.** The analysis of HIF-1 signaling pathway. Red color represents targets of *Epimedii Herba* of enrichment in the HIF-1 pathway.

**Figure 7.** The active component-target-pathway network of *Epimedii Herba* against AD. Yellow nodes represent active ingredients; blue nodes represent key targets; green arrows represent pathways; edges represent interactions among them.
Li Y. et al.: A network pharmacological approach to investigate…

© Med Sci Monit, 2020; 26: e926295

This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
Table 3. Docking of molecules with major target proteins.

| Target | PDB ID | Ligand | Three dimensional coordinates of the active site | Molecule | Affinity (kcal/mol) |
|--------|--------|--------|-------------------------------------------------|----------|---------------------|
| PTGS2  | 5KIR   | NAG    | x=23.59; y=2.418; z=34.258                      | Quercetin| –9.6                |
| MAPK1  | 4QP4   | 36O    | x=32.637; y=46.133; z=42.3                       | Quercetin| –8                  |
| TNF    | 6OOY   | A7M    | x=–11.496; y=1.548; z=–18.373                    | Luteolin | –10.6               |

Figure 8. Docking of key molecules with the major target proteins. (A) Molecular docking model of the Quercetin and Prostaglandin-endoperoxide synthase 2. (B) Molecular docking model of the Quercetin and Mitogen-activated protein kinase 1. (C) Molecular docking model of the Luteolin and Tumor necrosis factor alpha. The black dotted line and purple arrow in the figure represent hydrogen bonds and the blue dotted line and green arrow represent pi-pi stacking.

Discussion

In this study, 23 active components of *Epimedi Herba* were screened from the TCMSP database, among which 17 active components were associated with Alzheimer's disease. A variety of compounds have been reported in the literature. The main components of *Epimedi Herba* are flavonoids, and icariin is considered to be one of the main pharmacologically active components. Icariin can inhibit β-secretase activity, reduce the content of β-amyloid protein in the hippocampus and the mRNA level of β-secretase [29], improve cognitive function by...
inhibiting the loss of neurons and the formation of Aβ [30], inhibit nerve inflammation [31], inhibit atrophy of axons and dendrites [32], increase the content of neurotrophic factors, and promote the proliferation and differentiation of neural stem cells [33]. The cholinergic hypothesis is considered an important hypothesis in the process of AD. Epimedi Herba has been proved to inhibit AChE [34]. Studies have shown that long-term use of icariin can effectively improve cognitive dysfunction [30], indicating that icariin is important for the treatment of AD. The present study explored the potential mechanism of active ingredients in Epimedium for the treatment of AD, and provides a theoretical basis for the development of effective drugs in treatment of AD. Oxidative stress, inflammatory response, accumulation of β-amyloid protein, and hyperphosphorylation of tau protein play a crucial role in the progression of AD, leading to neurodegenerative changes [35–37].

Quercetin, one of the active ingredients in Epimedi Herba, can significantly reduce the expression of COX-2, iNOS, IL-1β, IL-6, and TNF-α, reduce inflammation [36], and can inhibit amyloid plaques and neurofibrillary tangles [38,39]. These data suggest that Epimedi Herba can effectively prevent and treat Alzheimer’s disease. Quercetin can improve the learning and memory levels in dementia rats and significantly reduce the level of hippocampal cell apoptosis [40]. Icariin can reduce Aβ accumulation, reduce the expression of related inflammatory mediators, improve learning and memory abilities, and maintain the ultrastructure hippocampal neurons [41]. Some active ingredients, such as kaempferol, chlorophenol, 8-(3-methylbutan-2-alkenyl)-2-phenylchromone, and linoleic acetate, have not been reported or are rarely reported in the literature, and they may become potential directions for future research on Epimedi Herba in the treatment of Alzheimer’s disease. It has been reported that kaempferol reduces glucose-induced oxidative stress in mouse hippocampal neuron HT22 cells by regulating B cell lymphoma 2 (Bcl-2), apoptosis-inducing factor (AIF), and mitogen-activated protein kinase (MAPK) [42]. Kaempferol can protect PC12 and T47D cells from β-amyloid-induced toxic effects [43], and protects PC12 cells from oxidative stress-induced cytotoxicity [44].

This study predicted 27 key targets for treating Alzheimer’s disease with PTGS2, 1L1B, MAPK1, GSK3β, TNF, PPARG, and VEGF. Among them, PTGS2 has been shown to play an important role in the progression of AD [45]. PTGS2 mediates the signal transduction pathway between glial cells and neuronal cells that regulates the interaction between IL-1β and Aβ, thereby inducing the aggravation of AD [46]. In contrast, PTGS2 inhibitors can reverse cognitive decline in AD by inducing neurogenesis and reducing apoptosis in transgenic mice [47]. IL1B can stimulate the synthesis of PTGS2. The metabolites of PTGS2 accelerate the phosphorylation of tau protein and the tangled deposition of nerve fibers, which can accelerate the AD process [48]. MAPK is a mitogen-activated protein kinase that can regulate cell functions, including cell proliferation, differentiation, survival, and apoptosis [49]. In late AD, MAPK1 is elevated. Hyperphosphorylation of tau in the progression of AD disease is a key factor in the generation of neurofibrillary tangles (NFT). Mitogen-activated protein kinase 1 (MAPK1) is thought to play a role in hyperphosphorylation [50]. Glycogen synthase kinase 3β (GSK3β) is involved in energy metabolism and neuronal cell development. The present study found that activation of GSK3β can lead to abnormal tau regulation and abnormal protein phosphorylation [51]. Tumor necrosis factor (TNF) is a pro-inflammatory factor that plays an important role in rheumatoid arthritis (RA) and many inflammatory diseases (such as Parkinson’s disease and AD) [52]. Inhibition of TNFR1 can reduce brain inflammation, so TNFR1 is a promising therapeutic target for AD [53]. Peroxisome proliferator-activated receptor γ (PPARG) is a functional effector that regulates metabolism and is related to the pathology of neurodegenerative diseases. Early PPARG targeted therapy in AD can suppress disease progression [54]. Pathological angiogenesis is considered to be a key factor in the development of AD. There is increasing evidence that neurodegenerative diseases are related to insufficiency of the brain [55–57], which can cause hypoxia in the brain and damage the parenchymal cells and the blood-brain barrier (BBB) [58]. VEGF is a key factor in angiogenesis, which can affect AD disease progression [59,60].

The quercetin with the highest degree was molecularly docked with the key target proteins, such as prostaglandin-peroxide synthase 2 (PTGS2) and mitogen-activated protein kinase 1 (MAPK1). The results showed that there was a strong affinity. Studies have shown that quercetin inhibits OA-induced hyperphosphorylation of tau protein and oxidative stress in HT22 hippocampal neurons through MAPK and PI3K/Akt/GSK3β signaling pathways, and has the potential to treat AD [61]. Quercetin also inhibits lipopolysaccharide-induced nitric oxide synthase (iNOS) and COX-2 gene expression, blocks the activation of nuclear factor κB [62], and plays a role in various inflammatory responses [63]. Quercetin has enhanced HO-1 protein expression, increased HO-1 mRNA expression, and reduced TNF-α levels. It can reduce inflammation [64]. Luteolin, one of the ingredients of Epimedium, can reduce cyclooxygenase 2 (COX-2), tumor necrosis factor alpha (TNF-α), interleukin 1 beta (IL-1 beta), interleukin 6 (IL-6) interleukin 8 (IL-8), and other inflammatory mediators, and increase the expression of cellular antioxidants Nrf2 and HO-1 [65]. Studies have found that luteolin can downregulate the phosphorylation of p38 MAPK [66]. Drug inhibitors of both P38 MAPK and ERK1/2 reduce the transcriptional activity of NF-κB and eliminate the subsequent COX-2 expression induced by Aβ [67]. In vitro studies also demonstrated that luteolin can inhibit β-secretase and reduce hyperphosphorylation of tau protein [68].
Key targets were enriched by KEGG to obtain pathways closely related to Alzheimer’s disease, such as the PI3K-Akt signaling pathway, HIF-1 signaling pathway, TNF signaling pathway, NF-κB signaling pathway, Toll-like receptor signaling pathway, and VEGF signaling pathway. This study shows the characteristics of multiple active ingredients, multi-targets, and multiple pathways of Epimedii Herba in the treatment of Alzheimer’s disease, which provides a theory for the clinical application of and further research on Epimedii Herba in the treatment of Alzheimer’s disease.

Conclusions
In summary, the potential targets and molecular mechanisms of Epimedii Herba in the treatment of Alzheimer’s disease were investigated through the network pharmacology system. Nine of the 27 key targets of Epimedii Herba against AD act on the HIF-1 signaling pathway. The HIF-1 signaling pathway is the key pathway of Epimedii Herba against Alzheimer’s disease. Studies have shown that M30, a new multifunctional iron chelator, activates the hypoxia-inducible factor (HIF)-1alpha signaling pathway and regulates the levels of the amyloid precursor protein, which has a potential neuroprotective effect [69].

Neurotropin® shows an effective neuroprotective effect by inhibiting Aβ-induced oxidative damage and reducing Aβ deposition in the hippocampus by regulating the HIF-1α/MAPK signaling pathway [70]. In conclusion, the present results may inspire and guide the next step in pharmacological and experimental research on Epimedii Herba in the treatment of Alzheimer’s disease.

Acknowledgments
We thank the Southwest Medical University Laboratory of Biochemistry and Molecular Biology for technical assistance.

Conflicts of interest
None.

References:
1. Ma H, He X, Yang Y et al: The genus Epimedium: An ethnomedical and phytochemical review. J Ethnopharmacol, 2011; 134(3): 519–41
2. Ye LC, Chen JM: [Advances in study on pharmacological effects of epimedium.] Zhongguo Zhong Yao Za Zhi, 2001; 26(5): 293–95 [in Chinese]
3. Li CH, Gao AS: [A review on treating Alzheimer’s disease in TCM.] Clinical Journal of Chinese Medicine, 2017; 9(28): 139–41 [in Chinese]
4. Wang S, Zhang X, Ma YR et al: [Clinical efficacy of bushen huatan yizhi decoction combined with butylphthalide and effect on oxidative stress, hemorheology and cognitive function in patients with Alzheimer’s Disease.] Chinese Journal of Experimental Traditional Medical Formulae, 2018; 24(07): 212–16 [in Chinese]
5. Reitz C, Mayeux R: Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem Pharmacol, 2014; 88(4): 640–51
6. Alzheimer’s Association: 2016 Alzheimer’s disease facts and figures. Alzheimer’s & Dementia, 2016; 12(5): 321–34
7. Mortamais M, Ash JA, Harrison J et al: Detecting cognitive changes in preclinical Alzheimer's disease. A review of its feasibility. Alzheimers Dement, 2018; 14(11): 1023–34
8. Meng Y, Zhang QL: Advances in active constituents of Traditional Chinese Medicines for treating Alzheimer's Disease. Letters in Biotechnology, 2015; 6: 24245
15. Xu X, Zhang W, Huang C et al: A novel chemometric method for the prediction of human oral bioavailability. Int J Mol Sci, 2012; 13(6): 6964–82
16. Liu H, Wang J, Zhou W et al: Systems approaches and polypharmacology for drug discovery from herbal medicines: An example using licorice. J Ethnopharmacol, 2013; 146(3): 773–93
17. He D, Huang JH, Zhang ZY et al: A network pharmacology-based strategy for predicting active ingredients and potential targets of liuwei dihuang pill in treating type 2 diabetes mellitus. Drug Des Devel Ther, 2019; 13: 3989–4005
18. Tao W, Xu X, Wang X et al: Network pharmacology-based prediction of the active ingredients and potential targets of Chinese herbal Radix Curcumae formula for application to cardiovascular disease. J Ethnopharmacol, 2013; 145(1): 1–10
19. Ru J, Li P, Wang J et al: TCMP: A database of systems pharmacology for drug discovery from herbal medicines. J Cheminform, 2014; 6: 13
20. Breuza L, Poux S, Estreicher A et al: The UniProtKB guide to the human proteome. Database (Oxford), 2016; 2016: bav120
21. Pinerio J, Queralt-Rosinach N, Bravo A et al: DisGeNET: A discovery platform for the dynamical exploration of human diseases and their genes. Database (Oxford), 2015; 2015: bav028
22. Safran M, Dalah I, Alexander J et al: GeneCards Version 3: the human gene integrator. Database (Oxford), 2010; 2010: baq020
23. Shannon P, Markiel A, Ozier O et al: Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res, 2003; 13(11): 2498–504
24. Szklarczyk D, Morris JH, Cook H et al: The STRING database in 2017: Quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res, 2017; 45(D1): D362–68
25. Huang da W, Sherman BT, Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc, 2009; 4(1): 44–57
26. Berman HM, Westbrook J, Feng Z et al: The protein data bank. Nucleic Acids Res, 2000; 28(1): 235–42
27. Warnecke A, Sandalova T, Achour A, Harris RA: PyTMs: A useful PyMOL plugin for modeling common post-translational modifications. BMC Bioinformatics, 2014; 15: 370
28. Trott O, Olson AJ: AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem, 2010; 312(5): 455–61
29. Nie J, Luo Y, Huang XN et al: Icarin inhibits beta-amyloid peptide segment 25-35 induced expression of beta-secretase in rat hippocampus. Eur J Pharmacol, 2010; 626(2–3): 213–18
30. Yan L, Deng Y, Gao J et al: Icariide ii effectively reduces spatial learning and memory impairments in Alzheimer’s disease model mice targeting beta-amyloid production. Front Pharmacol, 2017; 8: 106
31. Xiong D, Deng Y, Huang B et al: Icarin attenuates cerebral ischemia-reperfusion injury through inhibition of inflammatory response mediated by NF-kappaB, PPARalpha and PPARgamma in rats. Int Immunopharmacol, 2016; 30: 157–62
32. Urano T, Tohda C: Icarin improves memory impairment in Alzheimer’s disease model mice (5xFAD) and attenuates amyloid beta-induced neurite atrophy. Phytother Res, 2010; 24(11): 1658–63
33. Yao R, Zhang L, Xu L, Li L: Effects of Epimedium flavonoids on proliferation and differentiation of neural stem cells in vitro. Neurol Res, 2010; 32(7): 736–42
34. Jiang Y, Gao H, Turdu G: Traditional Chinese medicinal herbs as potential AChE inhibitors for anti-Alzheimer’s disease: A review. Bioorg Chem, 2017; 75: 50–61
35. Heneka MT, O’Banion MK: Inflammatory processes in Alzheimer’s disease. J Neuroimmunol, 2007; 184(1–2): 69–91
36. Lu J, Wu DM, Zheng YL et al: Quercetin activates AMP-activated protein kinase by reducing PP2C expression protecting old mouse brain against high cholesterol-induced neurotoxicity. J Pathol, 2010; 222(2): 199–212
37. Swayne AM, Forster S, Keeney JT et al: Abeta, oxidative stress in Alzheimer’s disease model rats. A pilot study. Front Cell Neurosci, 2015; 9: 148
38. Paula PC, Angelica Maria SG et al: Preventive effect of quercitin in a triple transgenic Alzheimer’s disease mice model. Molecules, 2019; 24(12): 2287
39. Lu J, Tian Q, Li Z et al: Activation of Nrf2 signaling by sitagliptin and quercetin combination against beta-amyloid induced Alzheimer’s disease in rats. Drug Dev Res, 2019; 80(6): 837–45
40. Li Y, Gu ZL, Chen YF et al: Study on relationship between effects of quercitin on learning and memory in Alzheimer’s disease rats and apoptosis of hippocampus cells. Chinese Traditional and Herbal Drugs, 2003; 7: 59–62
41. Guo L, Li J, Sun JT et al: Influence of icariin on ultrastructural changes of hippocampus in Alzheimer disease rat. Inner Mongolia Medical Journal, 2015; 40(8): 657–60
42. Yang EL, Kim GS, Mun J, Song KS: Kaempferol attenuates the glutamate-induced oxidative stress in mouse-derived hippocampal neuronal HT22 cells. Food Funct, 2014; 5(7): 1395–402
43. Roth A, Schaffner W, Hertel C: Phytoestrogen kaempferol (3,4’,5,7-tetrahydroxyflavone) protects PC12 and T47D cells from beta-amyloid-induced neurotoxicity. J Neurosci Res, 1999; 57(3): 399–404
44. Kim JK, Choi SJ, Cho HY et al: Protective effects of kaempferol (3,4’,5,7-tetrahydroxyflavone) against amyloid beta peptide (Abeta)-induced neurotoxicity in ICR mice. Biosci Biotechnol Biochem, 2010; 74(2): 397–401
45. Toral-Rios D, Franco-Bocanegra D, Rosas-Carrasco O et al: Evaluation of inflammatory-related genes polymorphisms in Mexican with Alzheimer’s disease: A pilot study. Front Cell Neurosci, 2015; 9: 148
46. Wang P, Guan PP, Wang T et al: Aggravation of Alzheimer’s disease due to the COX-2-mediated reciprocal regulation of IL-1beta and Abeta between giall and neuron cells. Aging Cell, 2014; 13(4): 605–15
47. Guo JW, Guan PP, Ding WY et al: Erythrocyte membrane-encapsulated cellectox improves the cognitive decline of Alzheimer’s disease by concurrently neurogenesis and reducing apoptosis in APP/PS1 transgenic mice. Biomaterials, 2017; 145: 106–27
48. Guan PP, Wang P: Integrated communications between cyclooxygenase-2 and Alzheimer’s disease. FASEB J, 2019; 33(1): 13–33
49. Pearson G, Robinson F, Beers Gibson T et al: Mitogen-activated protein (MAP) kinase pathways: Regulation and physiological functions. Endocr Rev, 2001; 22(2): 153–83
50. Gerschütz A, Heinen H, Grünblatt E et al: Neuron-specific alterations in signal transduction pathways associated with Alzheimer’s disease. J Alzheimers Dis, 2014; 40(1): 135–42
51. Ochalek A, Mikhalik B, Avci HK et al: Neurons derived from sporadic Alzheimer’s disease iPSCs reveal elevated tau hyperphosphorylation, increased amyloid levels, and GSK3B activation. Alzheimers Res Ther, 2017; 9(1): 90
52. Probst L: TNF and its receptors in the CNS: The essential, the desirable and the deleterious effects. Neuroscience, 2015; 302: 2–22
53. Steeland S, Gorle N, Vandendriessche C et al: Counteracting the effects of TNF-receptor-1 has therapeutic potential in Alzheimer’s disease. EMBO Mol Med, 2018; 10(4): e83100
54. Wang S, Guan L, Luo D et al: Gene–gene interaction between PPARG and APOE gene on late-onset Alzheimer’s disease: A case-control study in Chinese Han population. J Nutr Health Aging, 2017; 21(4): 397–403
55. Skrobot OA, Attems J, Esiri M et al: Vascular cognitive impairment neuro-pathology guidelines (VCING): the contribution of cerebrovascular pathology to cognitive impairment. Brain, 2016; 139(11): 2957–69
56. Schuff N, Matsumoto S, Kmieciak J et al: Cerebral blood flow in ischemic vascular dementia and Alzheimer’s disease, measured by arterial spin-labeling magnetic resonance imaging. Alzheimers Dement, 2009; 5(6): 454–62
57. Kalaria RN: Neuropathological diagnosis of vascular cognitive impairment and vascular dementia with implications for Alzheimer’s disease. Acta Neuropathol, 2016; 131(5): 659–85
58. Sweeney MD, Sagare AP, Zlokovic BV: Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat Rev Neurol, 2018; 14(3): 133–50
59. De Marco LY, Venneri A, Barkas E et al: Vascular dysfunction in the pathogenesis of Alzheimer’s disease: A review of endothelium-mediated mechanisms and ensuing vicious circles. Neurobiol Dis, 2015; 82: 593–606
60. Harris R, Miners JS, Allen S, Love S: VEGFR1 and VEGFR2 in Alzheimer’s disease. J Alzheimers Dis, 2018; 61(2): 741–52
61. Jiang W, Luo T, Li S et al: Quercetin protects against okadaic acid-induced injury via MAPK and PI3K/Akt/GSK3beta signaling pathways in HT22 hippocampal neurons. PLoS One, 2016; 11(4): e0152371
62. Patil CS, Singh VP, Satyanarayan PS et al: Protective effect of flavonoids against aging- and lipopolysaccharide-induced cognitive impairment in mice. Pharmacology, 2003; 69(2): 59–67
63. Liang YC, Tsai SH, Tsai DC et al: Suppression of inducible cyclooxygenase and nitric oxide synthase through activation of peroxisome proliferator-activated receptor-gamma by flavonoids in mouse macrophages. FEBS Lett, 2001; 496(1): 12–18
64. Sun GY, Chen Z, Jasmer KJ et al: Quercetin attenuates inflammatory responses in BV-2 microglial cells. Role of MAPKs on the NFκB pathway and induction of heme oxygenase-1. PLoS One, 2015; 10(10): e0141509
65. Rakariyatham K, Wu X, Tang Z et al: Synergism between luteolin and sulforaphane in anti-inflammation. Food Funct, 2018; 9(10): 5115–23
66. Zhang JX, Xing JG, Wang LL et al: Luteolin inhibits fibrillary beta-Amyloid1-40-induced inflammation in a human blood–brain barrier model by suppressing the p38 MAPK-mediated NF-kappaB signaling pathways. Molecules, 2017; 22(3): 334
67. Jiang JH, Surh YJ: Beta-amyloid-induced apoptosis is associated with cyclooxygenase-2 up-regulation via the mitogen-activated protein kinase-NF-kappaB signaling pathway. Free Radic Biol Med, 2005; 38(12): 1604–13
68. Sawmilller D, Li S, Shahaduzzaman M et al: Luteolin reduces Alzheimer’s disease pathologies induced by traumatic brain injury. Int J Mol Sci, 2014; 15(1): 895–904
69. Avramovich-Tirosh Y, Bar-Am O, Amrit T et al: Up-regulation of hypoxia-inducible factor (HIF)-1alpha and HIF-target genes in cortical neurons by the novel multifunctional iron chelator anti-Alzheimer drug, M30. Curr Alzheimer Res, 2010; 7(6): 300–6
70. Fang WL, Zhao DQ, Wang F et al: Neurotrophin(R) alleviates hippocampal neuron damage through a HIF-1alpha/MAPK pathway. CNS Neurosci Ther, 2017; 23(5): 428–37